Zacks Investment Research | Sep 19, 2019 09:46PM ET
The market for devices providing solutions for detection and treatment of sleep apnea – a potentially serious sleep disorder – has gained investors’ attention due to the prospects it presents. This market holds huge untapped potential considering the fact that 80% of the cases of moderate and severe obstructive sleep apnea (OSA) are still undiagnosed (industry ’s rally of 14.5%.
ResMed Inc. (NYSE:RMD) holds a major position as a designer, manufacturer and distributor in the worldwide market for generators, masks and related accessories for the treatment of sleep-disordered breathing and other respiratory disorders, including OSA and other sleep-related respiratory disorders. In April 2019, the company unveiled its first top-of-head connected nasal pillows mask — AirFit P30i — in the United States. This is the company’s second top-of-head connected Continuous Positive Airway Pressure (CPAP) mask designed to treat sleep apnea.
This Zacks Rank #3 (Hold) company has a long-term earnings growth rate of 10.6%. For fiscal 2020, the Zacks Consensus Estimate for revenues is pegged at $2.86 billion, indicating an improvement of 9.9% from the year-ago period.
Over the past year, ResMed’s shares have gained 17.3%, against the industry ’s decline of 0.7%.
Natus Medical Incorporated (NASDAQ:NTUS) – a leading provider of healthcare products – boasts of a Neuro business unit that offers a comprehensive portfolio of sleep solutions. It includes in-lab testing products like Natus SleepWorks Software, Xltek Brain Monitor Amplifier, to name a few.
This Zacks Rank #3 company witnessed its 2019 earnings estimate move upward by 0.8% in the past two months to $1.28 per share.
Over the past six months, shares of Natus Medical have gained 15.7%, against the industry ’s decline of 4.6%.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.